SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion, primarily driven by the ongoing, contentious acquisition saga surrounding Warner Bros. Discovery, which continues to generate significant uncertainty. This prolonged situation, compounded by mixed analyst sentiment, has led to sharply divided investor opinions, with many debating the stock's "oversold" status as it navigates a challenging environment ahead of its earnings report.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is actively trending as its passionate community rallies behind its audacious goal to become the top memecoin, aiming to surpass established players like Dogecoin. Discussions highlight its deflationary token burns and strong presence across the Solana and Cronos chains, driving fervent "bullish" sentiment despite some skepticism.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is generating significant buzz, driven by discussions around CEO Ryan Melsert's influential role in G7 critical metals strategies and the broader trend of rising lithium prices. The community is actively discussing the company's "made in USA" battery recycling initiatives, anticipating substantial government support and key project milestones, which are fueling expectations for its future growth in the domestic supply chain.

KOLANA is a koala-character meme coin that has been designed as the newest meme character token to join the Solana ecosystem. It’s a fun, community-driven token with no inherent value, created purely for those who want to participate in the Solana meme culture and become a part of the KOLANA community. While it doesn't offer utility or financial promises, it thrives on community engagement and decentralised fun.

KOLANA

KOLANA CRYPTO is capturing significant community interest, driven by discussions around its clear technical levels and steady momentum. Many are expressing enthusiasm for potential early entry, indicating a growing speculative sentiment around the asset.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is generating intense market conversation and significant volatility due to a recent FDA request for additional data to further characterize FILSPARI's clinical benefit for its potential FSGS indication, despite the company reiterating confidence and reporting robust sales for its existing IgAN approval. This immediate uncertainty has polarized the community, with many speculating on a Complete Response Letter (CRL) while others perceive the sharp sell-off as an overreaction, viewing it as a buying opportunity given the high unmet medical need in FSGS.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

Lulus Fashion Lounge (LVLU) is trending due to activist investor Christian Friedland's disclosed stake and call for significant governance reforms, emphasizing the company's "extremely undervalued" status. The community is actively discussing Friedland's assertion that LVLU trades at a 27x valuation gap compared to peers, despite achieving positive adjusted EBITDA and expanded gross margins. This has ignited speculation among traders about a potential "super squeeze" and multi-day run, driven by the proposed reforms and perceived undervaluation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is surging with massive trading volume after reporting impressive preliminary Q4 and full-year revenue estimates that surpassed guidance, alongside projections for Adjusted EBITDA positivity. The community is actively discussing the sustainability of this breakout, with many anticipating further upside, while some express caution about dilution risks despite significant insider share accumulation signaling strong confidence. This interest is amplified by the company's position in the precision lung diagnostics sector.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as the bank kicks off earnings season, with community discussions intensely focused on recent warnings about rising expenses and the potential impact of a proposed credit card interest rate cap. Investors are also digesting the bank's strategic move to take over the Apple Card program and its deeper foray into blockchain and tokenized funds, all while online chatter includes speculation regarding its market positions in commodities.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is experiencing significant bullish momentum, propelled by a recent analyst price target upgrade and its pivotal role within the expanding space and defense sectors. The community is actively discussing the company's substantial revenue, robust backlog, and the potential for a short squeeze as the stock navigates key technical resistance levels. Many investors view RDW as an undervalued asset, strategically positioned as an essential infrastructure provider within the thriving space economy.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining attention following a new pre-production order for GPU-accelerated systems for U.S. Army combat vehicles, which is amplifying community anticipation for a much larger defense contract in the burgeoning Edge AI sector. Investors are bullish on the company's focused strategy after a recent asset sale, coupled with its specialized technology, low stock float, and potential for significant growth in defense and AI infrastructure. Discussions highlight the company's strong positioning for future defense spending and AI compute needs at the tactical level.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced their target price on Neurocrine Biosciences from $179.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday...

Neurocrine Biosciences, Inc. $NBIX Stock Holdings Increased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 86.7% in the 3rd quarter, according to the company in its most...

Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX

Cerity Partners LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 76.3% during the third quarter, according to the company in its most recent filing with...

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $169.00 at Truist Financial

Truist Financial lowered their price objective on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a "buy" rating for the company in a research report on Thursday...

Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO...

<ul class="summary-bullets"><li>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.</li><li>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates."</li><li>Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</li></ul><p>Crinetics Pharmaceuticals, Inc. (CRNX) said on Monday that its experimental drug Atumelnant yielded positive results in the fourth cohort of a congenital adrenal hyperplasia trial (CAH), sending shares up 3% in Monday’s mid-day trading. &nbsp;</p><p>Atumelnant is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic congenital adrenal hyperplasia as well as adrenocorticotropic hormone-dependent Cushing’s syndrome.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3212693/0/en/Crinetics-Announces-Strong-PALSONIFY-Launch-Execution-and-Positive-Results-for-Concurrent-Androstenedione-Lowering-and-Glucocorticoid-Dose-Reduction-in-Phase-2-Trial-of-Atumelnant-.html?_gl=1*dclqt*_up*MQ..*_ga*MTQ5MTU3MjU2MS4xNzY3NjMzMDE2*_ga_ERWPGTJ5X8*czE3Njc2MzMwMTUkbzEkZzAkdDE3Njc2MzMwMjIkajUzJGwwJGgw">said</a> that treatment with Atumelnant resulted in rapid, sustained lowering of androstenedione in all eight patients that completed the fourth cohort of the mid-stage trial.</p><p>Shares of Neurocrine Biosciences (NBIX), whose Crenessity drug is approved for CAH, fell by 3% following the rival’s update.</p><h2 class="st-heading-2">Trial Results</h2><p>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with CAH caused by 21-hydroxylase deficiency. CAH is a group of genetic disorders affecting the adrenal glands, preventing them from producing enough cortisol and aldosterone. It leads to issues with energy, blood sugar, blood pressure, salt/water balance, and sexual development.</p><p>The drug was observed to be well-tolerated, with no serious adverse events and no treatment-related severe adverse events, the company added.</p><h2 class="st-heading-2">Positive Feedback For Palsonify</h2><p>Separately, Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</p><p>Palsonify was approved by the U.S. Food and Drug Administration (FDA) on September 25 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.</p><p>The company noted that feedback from patients, physicians and payers have been positive thus far.</p><h2 class="st-heading-2">Expert Take</h2><p>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates," as per TheFly.</p><p>The firm believes the Atumelnant update will be "much more impactful" for the stock today as it contends that Crinetics "again looks to comfortably have 2 blockbuster," high odds of success products and more in earlier development.</p><p>RBC Capital analyst Brian Abrahams noted that the data looked very supportive of the drug's ability to be a potential competitor that could reach the CAH market within the next few years, according to TheFly. However, the firm believes comparing the dataset to Neurocrine's phase III study data is limited, primarily due to the differences in patient population. Overall, RBC notes that while competitor data reaffirms a potential emerging player in the CAH space, this was already well known, patient stickiness may shield Crenessity from future competition. Even with conservative estimates, it sees Crenessity contributing $1.1 billion to Neurocrine's revenue stream in the U.S. market alone.</p><p>RBC added that it would be a buyer of Outperform-rated Neurocrine on weakness.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around CRNX stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/NBIX">NBIX stock</a> stayed within the ‘bearish’ territory in the same time.</p><p><a href="https://stocktwits.com/symbol/CRNX">CRNX stock</a> has dropped 5% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-q4-deliveries-dive-on-lower-ev-sales/cmxMtAZR4RJ">General Motors Q4 Deliveries Dive On Lower EV Sales — Automaker Looks To Next-Generation Bolt EV For Bounceback</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.

Equity

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.


Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Down - Here's Why

Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Down - Here's What Happened...

Stanley Laman Group Ltd. Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX

Stanley Laman Group Ltd. trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.4% during the third quarter, according to the company in its most recent 13F filing...

Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX

Merit Financial Group LLC boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 101.3% during the third quarter, according to the company in its most recent...

Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

Braun Stacey Associates Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 7.4% in the 3rd quarter, according to its most recent filing with the...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

NBIX
Neurocrine Biosciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NBIX News

NBIXNeurocrine Biosciences, Inc.